U.S FDA has accepted the IND application for ASN007, a selective ERK ½ inhibitor as declared by Asana BioSciences which specialises in oncology nd a clinical stage biopharmaceutical company.
Sandeep Gupta, PhD, Founder, President and Chief Executive Officer at Asana BioSciences says “We continue to execute on our strategy of developing novel drugs that work on clinically validated targets, are clearly differentiated from the competition, and expected to offer significant benefit over the existing standards of care. This represents the 5th successful IND of our proprietary portfolio in the past 3 years, and is a testament to the capabilities, dedication and high efficiency of Asana’s R&D team,
The RAS/RAF/MEK/ERK (MAP Kinase) suggesting pathway is frequently hyperactivated in an extensive array of cancers through mutations in upstream targets such as BRAF, RAS and receptor tyrosine kinases. Inhibition of ERK1/2 offers a dedicated therapeutic strategy for these cancers, particularly those driven by RAS mutations. Enrollment in this Phase 1, open-label, dose-finding study of ASN007 in patients with advanced solid tumors is expected to herald soon. The study is likely to test the safety, tolerance and effectiveness of ASN007 in patients afflicted with BRAF,KRAS,HRAS,NRAS mutations.